Patient Links

Personalizing Treatment for Papillary Thyroid Cancer

Clinicians treating papillary thyroid cancer must consider many factors to determine the best treatment for you. One of the most important factors they must consider is their estimate of the likelihood that the cancer will return (also known as risk recurrence). This is because cancers with a high risk of recurrence are treated more aggressively. Estimating the chances that the cancer will come back is difficult.

Thyroid GuidePx® is a molecular test that makes risk estimation simple and accurate.

Play Video

Introduction to Thyroid GuidePx® for Patients

Scientific Evidence

Thyroid GuidePx®, validated and run through our CAP/CLIA laboratory accredited partner, Protean Biodiagnostics, ensures consistent and accurate results. We invite you to explore the studies that support our test. These studies demonstrate the rigorous scientific research and proven clinical value of our test.

Play Video

Papillary Thyroid Cancer

About Papillary
Thyroid Cancer

The incidence of thyroid cancer is increasing by about 6% per year.  Papillary thyroid cancer, the most common type of thyroid cancer, is not usually life-threatening. Still, recurrence after treatment can significantly affect the quality of life.

Identifying high-risk individuals helps to direct appropriately aggressive treatment to those who need it. At the same time, confidently identifying individuals with a very low risk of recurrence will help select when more conservative treatment can be offered.

Contact Us

Need more information? Get in touch!

How to Order

How Do I Order the Thyroid GuidePx® Test?

  1. Access requisition form by clicking here.
  2. Print off requisition form.
  3. Fax completed form to Protean BioDiagnostics at (877) 764-7628.
  4. A Protean team member will confirm receipt of the test requisition form by email or phone call and discuss your next steps.